DK3399984T3 - Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf - Google Patents

Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf Download PDF

Info

Publication number
DK3399984T3
DK3399984T3 DK17736459.3T DK17736459T DK3399984T3 DK 3399984 T3 DK3399984 T3 DK 3399984T3 DK 17736459 T DK17736459 T DK 17736459T DK 3399984 T3 DK3399984 T3 DK 3399984T3
Authority
DK
Denmark
Prior art keywords
nucleotidase
ecto
modulators
Prior art date
Application number
DK17736459.3T
Other languages
English (en)
Inventor
Laurent Pierre Paul Debien
Juan Carlos Jaen
Jaroslaw Kalisiak
Kenneth V Lawson
Manmohan Reddy Leleti
Erick Allen Lindsey
Dillon Harding Miles
Eric Newcomb
Jay Patrick Powers
Brandon Reid Rosen
Ehesan Ui Sharif
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Application granted granted Critical
Publication of DK3399984T3 publication Critical patent/DK3399984T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
DK17736459.3T 2016-01-08 2017-01-06 Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf DK3399984T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276564P 2016-01-08 2016-01-08
US201662324077P 2016-04-18 2016-04-18
PCT/US2017/012587 WO2017120508A1 (en) 2016-01-08 2017-01-06 Modulators of 5'-nucleotidase, ecto and the use thereof

Publications (1)

Publication Number Publication Date
DK3399984T3 true DK3399984T3 (da) 2023-11-13

Family

ID=59274491

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17736459.3T DK3399984T3 (da) 2016-01-08 2017-01-06 Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf

Country Status (28)

Country Link
US (4) US10239912B2 (da)
EP (2) EP3399984B1 (da)
JP (3) JP6920344B2 (da)
KR (1) KR20180100638A (da)
CN (2) CN114395005A (da)
AU (2) AU2017206061B2 (da)
BR (1) BR112018013827B1 (da)
CA (2) CA3009196C (da)
CL (1) CL2018001845A1 (da)
DK (1) DK3399984T3 (da)
EA (1) EA038565B1 (da)
ES (1) ES2963759T3 (da)
FI (1) FI3399984T3 (da)
HR (1) HRP20231155T1 (da)
HU (1) HUE063388T2 (da)
IL (1) IL260260B2 (da)
LT (1) LT3399984T (da)
MX (2) MX2018008350A (da)
PH (1) PH12018501361A1 (da)
PL (1) PL3399984T3 (da)
PT (1) PT3399984T (da)
SA (1) SA518391985B1 (da)
SG (1) SG11201805506YA (da)
SI (1) SI3399984T1 (da)
TW (2) TWI744274B (da)
UA (1) UA124529C2 (da)
WO (1) WO2017120508A1 (da)
ZA (2) ZA201804350B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963759T3 (es) 2016-01-08 2024-04-01 Arcus Biosciences Inc Moduladores de la 5'-nucleotidasa, ecto y su uso
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
HRP20220468T1 (hr) 2016-12-08 2022-05-27 F. Hoffmann - La Roche Ag Novi derivati izoksazolil etera kao gaba a alpha5 pam
CN110402249A (zh) * 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TWI702954B (zh) * 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
JP7417530B2 (ja) * 2018-03-09 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド 優先投与される免疫増強薬
MX2020011542A (es) * 2018-04-30 2020-11-24 Oric Pharmaceuticals Inc Inhibidores de cd73.
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
WO2020037275A1 (en) * 2018-08-17 2020-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors
US11332492B2 (en) 2018-08-28 2022-05-17 Jiangsu Hengrui Medicine Co., Ltd. CD73 inhibitors and therapeutic uses thereof
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
US10881681B2 (en) 2018-09-11 2021-01-05 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
US11819512B2 (en) 2018-12-13 2023-11-21 Arcus Biosciences, Inc. Solid forms of a CD73 inhibitor and the use thereof
WO2020151707A1 (zh) * 2019-01-22 2020-07-30 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
CN113795267A (zh) * 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
EP3947463A4 (en) * 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
WO2020205538A1 (en) * 2019-03-29 2020-10-08 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
JP2022527556A (ja) * 2019-04-05 2022-06-02 プレリュード・セラピューティクス・インコーポレイテッド プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
WO2020210970A1 (en) * 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
MX2022002398A (es) * 2019-08-29 2022-03-17 Lilly Co Eli Formas cristalinas de un inhibidor de cd73.
KR102653726B1 (ko) * 2019-10-30 2024-04-01 오릭 파마슈티칼스, 인크. Cd73 억제제
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
JP7474861B2 (ja) 2020-03-19 2024-04-25 アーカス バイオサイエンシーズ，インコーポレーテッド Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022007677A1 (zh) * 2020-07-07 2022-01-13 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
EP4212524A1 (en) * 2020-09-08 2023-07-19 Betta Pharmaceuticals Co., Ltd Cd73 inhibitor and application thereof in medicine
CN114437039A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 Cd73抑制剂及其应用
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CN114539340A (zh) * 2020-11-25 2022-05-27 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
CN116546990A (zh) * 2020-11-25 2023-08-04 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
KR20230125800A (ko) * 2020-12-29 2023-08-29 쩌지앙 빔그린 파머슈티컬스, 엘티디 A3 아데노신 수용체 작용제 및 이의 제조 방법과 용도
CN117642411A (zh) * 2021-05-11 2024-03-01 西藏海思科制药有限公司 小分子cd73拮抗剂及其用途
EP4341261A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl compounds
TW202313603A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
WO2023061319A1 (zh) * 2021-10-11 2023-04-20 南京明德新药研发有限公司 三并环杂环衍生物
CA3235405A1 (en) * 2021-10-26 2023-05-04 Omar MOUKHA-CHAFIQ Development of novel clofarabine analogs for cancer therapy
US20230159466A1 (en) 2021-10-29 2023-05-25 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
CN1113888C (zh) * 1996-10-09 2003-07-09 法玛塞特有限公司 四膦酸酯二环三酸酐
AU2002232660A1 (en) * 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2012032513A1 (en) * 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
JP6903432B2 (ja) 2014-03-12 2021-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
EA033613B1 (ru) 2015-08-17 2019-11-08 Lupin Ltd Гетероарильные производные в качестве ингибиторов parp
ES2963759T3 (es) 2016-01-08 2024-04-01 Arcus Biosciences Inc Moduladores de la 5'-nucleotidasa, ecto y su uso
UY37062A (es) 2016-01-08 2017-08-31 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
WO2017120422A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
JP7417530B2 (ja) 2018-03-09 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド 優先投与される免疫増強薬
US11819512B2 (en) 2018-12-13 2023-11-21 Arcus Biosciences, Inc. Solid forms of a CD73 inhibitor and the use thereof
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Also Published As

Publication number Publication date
UA124529C2 (uk) 2021-10-05
EP3399984A1 (en) 2018-11-14
HUE063388T2 (hu) 2024-01-28
US20190309010A1 (en) 2019-10-10
US10981944B2 (en) 2021-04-20
US20210371449A1 (en) 2021-12-02
US11667662B2 (en) 2023-06-06
PL3399984T3 (pl) 2024-02-19
CN114395005A (zh) 2022-04-26
WO2017120508A8 (en) 2018-07-05
US10239912B2 (en) 2019-03-26
EP4306525A3 (en) 2024-03-20
CA3009196C (en) 2022-05-31
JP6920344B2 (ja) 2021-08-18
CN108697719A (zh) 2018-10-23
JP2021167351A (ja) 2021-10-21
US11001603B2 (en) 2021-05-11
SI3399984T1 (sl) 2024-01-31
TW201805006A (zh) 2018-02-16
PT3399984T (pt) 2023-11-21
CN108697719B (zh) 2024-03-19
HRP20231155T1 (hr) 2024-01-05
FI3399984T3 (fi) 2023-11-10
TWI744274B (zh) 2021-11-01
MX2018008350A (es) 2019-05-30
JP2023129628A (ja) 2023-09-14
LT3399984T (lt) 2023-11-10
TW202227095A (zh) 2022-07-16
KR20180100638A (ko) 2018-09-11
ZA202209472B (en) 2023-06-28
EP3399984A4 (en) 2020-01-01
EP4306525A2 (en) 2024-01-17
WO2017120508A1 (en) 2017-07-13
US20170267710A1 (en) 2017-09-21
EP3399984B1 (en) 2023-09-06
CL2018001845A1 (es) 2018-12-07
BR112018013827B1 (pt) 2024-02-20
IL260260B2 (en) 2024-01-01
MX2022006322A (es) 2022-06-22
AU2017206061A8 (en) 2018-07-26
SA518391985B1 (ar) 2022-12-19
CA3151595A1 (en) 2017-07-13
CA3009196A1 (en) 2017-07-13
BR112018013827A2 (pt) 2018-12-11
IL260260B1 (en) 2023-09-01
EA038565B1 (ru) 2021-09-15
EA201891583A1 (ru) 2019-01-31
SG11201805506YA (en) 2018-07-30
US20210002322A1 (en) 2021-01-07
ES2963759T3 (es) 2024-04-01
IL260260A (en) 2018-07-31
PH12018501361A1 (en) 2019-02-27
JP2019501223A (ja) 2019-01-17
AU2017206061A1 (en) 2018-07-19
JP7322104B2 (ja) 2023-08-07
ZA201804350B (en) 2023-11-29
AU2017206061B2 (en) 2022-12-15
AU2023201288A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
DK3399984T3 (da) Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3872085T3 (da) Stam-virussekvenser og anvendelser heraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3484865T3 (da) Somatostatinmodulatorer og anvendelser deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3364958T3 (da) Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
MA46717A (fr) Variantes de l'endonucléase homing tcra
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
DK3458471T3 (da) Variant-flavivirus-kappesekvenser og anvendelser deraf
DK3601263T3 (da) Hidtil ukendte pyridazinonherbicider
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3448419T3 (da) Interferon-beta-antistoffer og anvendelser deraf
MA41864A (fr) Variants de protoxine ii et leurs méthodes d'utilisation
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3468964T3 (da) Modulatorer af SOCE, sammensætninger og anvendelser deraf
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi